Anecortave acetate

Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2].

Product Specifications

CAS Number

[7753-60-8]

Product Name Alternative

Anecortave

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

PAI-1

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/anecortave-acetate.html

Purity

99.81

Solubility

Methanol : 1 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](O)(CC[C@]1([C@@]3(CCC4=CC(CC[C@@]4(C3=CC2)C)=O)[H])[H])C(COC(C)=O)=O

Molecular Formula

C23H30O5

Molecular Weight

386.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S26-34.|[2]Penn JS, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001 Jan;42 (1) :283-90.